The authors concluded that the different responses in the two models could result from differences in intrinsic immunogenicity of the different tumor entities and that anti-CD137 antibodies may not only be used as a stand-alone therapy but in combination with conventional anti-cancer treatments, e.g., RT (114). Here, TNFRSF9 is linked to neoplasm.